Friday, 23 Aug 2019

You are here

Drug-Induced Lupus is Rare with TNF inhibitor Therapy

Drug-induced lupus (DIL) has been associated with all TNF inhibitors. Early rates suggested this may be between 0.04 - 0.06 events per 100 patient-years or roughtly 5 per 1000 patient-years. Jani and coworkers presented their analysis of the BSRBR biologics registry presented at the annual British Society of Rheumatology meeting. They found being female, non-white and having higher disease activity were predictive factors for DIL with TNFi. Cutaneous lupus manifestations were common. The found a 3-fold higher risk for patients on TNFi, with a crude event rate of 10 per 10,000 patient years (versus 3 per 10,000 PY on DMARDs alone). 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.

FDA Adds Boxed Warning to Sleep Drugs

The Food and Drug Administration (FDA) added a Boxed Warning to several sleep medications (e.g., eszopiclone, zaleplon, and zolpidem), warning rare but serious injuries may occur as a result of abnormal sleep behaviors (sleepwalking, sleep driving, and engaging in other activities while not fully awake) when taking sleep medications. These complex sleep behaviors have also resulted in deaths.